Skip to content
DataLookout
Menu

NCT07567742

Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 19 words
    • Start date changed from estimate of May 6, 2026 to May 8, 2026
    • Secondary endpoints: details revised at 5 of 8 entries
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of Severe Radiation-Induced Oral Mucositis
Timeframe: From the start of radiotherapy to 4 weeks after completion of radiotherapy

Secondary (8)

Onset Time of Severe Radiation-Induced Oral Mucositis
Duration of Severe Radiation-Induced Oral Mucositis
Recovery Rate of Severe Radiation-Induced Oral Mucositis
Incidence of Radiation-Induced Oral Mucositis
Incidence of Radiotherapy Interruption
Show 3 moreShow less
Quality of life (QoL)
Numeric Rating Scale for Pain
Safety as Assessed by CTCAE

Arms and interventions

TaurineExperimental

Oral taurine 1 g twice daily, starting 3 days before radiotherapy until 1 week after completion of radiotherapy, plus standard of care for RIOM.

ControlNo intervention

Patients in the control arm will receive the standard of care for RIOM.

Drugs: Taurine

Sites

1 site in 1 country

  • Sun Yat-sen University Cancer CenterGuangzhou, Guangdong, China